Perspective Therapeutics, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Perspective Therapeutics, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2023	FY2024	FY2025
Revenue	4.76	5.92	7.31	9.68	10.1	10.8	0	1.43
Cost of revenue	3.92	4.08	4.27	4.56	4.93	6.18
Gross profit	0.84	1.84	3.05	5.12	5.12	0	0	1.43
Research and development	0.97	1.75	1.47	1.13	1.43	0.85	0.88	21.3	41.6	84.2
Selling and marketing	2.31	2.66	2.68	2.98	2.44	2.8
General and administrative	3.92	4.17	4.17	4.57	4.69	5.57	7.49	21.1	26.6	30.2
Operating expenses	7.15	8.57	8.3	8.6	8.57	6.42	8.67	42.4	92.3	114
Operating income	-6.31	-6.73	-5.25	-3.48	-3.45	-6.42	-8.67	-40.9	-90.9	-114
Interest expense	0					0	0	0.08
Interest income	0.12	0.03	0.11	0.03	0.06	0.12	0.62	0.93	10.5	8.11
Other non-operating income	0.15	0.03	0.11	0.03	0.06	0.12	0.62	0.84	10.5	9.14
Pre-tax income						-6.3	-8.05	-40.1	-80.4	-104
Income tax	0	0	0	0	0	0	0	-2.65	-2.1	-0.79
Net income	-6.16	-6.7	-5.14	-3.45	-3.39	-7.27	-10.8	-46.5	-79.3	-103
EBITDA	-6.24	-6.65	-5.12	-3.33	-3.3	-6.17	-8.41	-40	-88.6	-110
EPS, basic	-1.13	-1.23	-0.82	-0.51	-0.31	-0.51	-0.82	-1.74	-1.23	-1.40
EPS, diluted	-1.13	-1.23	-0.82	-0.51	-0.31	-0.51	-0.82	-1.74	-1.23	-1.40
Shares, basic (weighted)	5.38	5.39	6.55	6.6	10.1	13.9	13.9	26.8	64.4	73.8
Shares, diluted (weighted)	5.38	5.39	6.55	6.6	10.1	13.9	13.9	26.8	64.4	73.8

Balance sheet

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2023	FY2024	FY2025
Cash and equivalents	5.93	2.6	5.33	2.39	63.8	55.9	21	9.24	61.6	30.6
Short-term investments	3.04	0.83			0	0	22.8	0	165	114
Receivables	0.73	1.19	1.15	2.04	2.01	1.61	1.36	1.17	0.12	0.01
Inventory	0.32	0.49	0.53	0.65	0.98	1.4	1.41
Other current assets	0.03	0.03	0.03	0.03	0.03	0.03	0	0.05	0.08	0.04
Total current assets	10.3	5.45	7.32	5.51	67.3	59.3	53.2	16.8	231	148
Property, plant and equipment	1.05	1.31	1.61	1.74	1.96	1.98	0.37	5.58	57.3	76.6
Lease right-of-use assets				1	0.77	0.51	0	0.75	2.22	1.5
Goodwill							0	24.1	0
Intangible assets	0.23	0.2	0.16	0.14	0.13	0.11	0.03	0.35	0.28	0.36
Long-term investments	0
Other non-current assets	0.23	0.2	0.16	0.14	0.13	0.11	0.18	0.49	0.41	0.49
Total assets	12.3	7.46	9.42	8.7	70.4	64.4	58.1	97.9	341	267
Accounts payable	0.63	1.39	0.68	0.65	0.73	0.97	1.54	6.91	10.3	20.5
Accrued liabilities	0.14	0.16						3.59	5.48	7.49
Total current liabilities	1.11	1.84	1.12	1.58	1.8	2.27	3.12	15.7	18.2	28.7
Long-term debt							0	1.68	1.63	1.57
Lease liabilities				0.77	0.52	0.26	0	0.78	1.43	1.01
Other non-current liabilities								0	0.06	0.39
Total liabilities	1.67	2.43	1.74	2.98	3.01	3.16	3.45	22.7	50.4	59.9
Total debt								1.73	1.68	1.63
Paid-in capital	83.2	84.3	92.1	93.6	159	160	160	228	522	542
Retained earnings	-72.6	-79.3	-84.5	-87.9	-91.3	-98.6	-106	-152	-232	-335
Other comprehensive income									-0.05	0.11
Shareholders' equity	10.6	5.03	7.68	5.72	67.4	61.3	54.6	75.2	291	207
Total equity	10.6	5.03	7.68	5.72	67.4	61.3	54.6	75.2	291	207
Total liabilities and equity	12.3	7.46	9.42	8.7	70.4	64.4	58.1	97.9	341	267
Shares outstanding	5.38	5.5	6.58	6.73	13.9	13.9	13.9	28.2	70.7	74.3

Cash flow statement

	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2023	FY2024	FY2025
Net income	-6.16	-6.7	-5.14	-3.45	-3.39	-7.27	-10.8	-46.5	-79.3	-103
Depreciation and amortization	0.07	0.08	0.14	0.15	0.15	0.25	0.27	0.99	2.31	3.25
Stock-based compensation	0.37	0.4	0.42	0.5	0.39	1.09	0.98	3.74	5.39	8.97
Deferred income tax						0	0	-2.65	-2.1	-0.79
Change in receivables	-0.18	-0.47	0.04	-0.89	0.03	0.41	0.28	0.2	1.05	0.11
Change in inventory	0.09	0.02	0.13	-0.1	-0.27	-2.67	-2	0.36
Change in payables	0.02	0.76	-0.71	-0.03	0.08	0.24	0.69	1.57	1.89	0.15
Cash from operations	-5.71	-5.71	-5.05	-3.64	-2.84	-7.71	-10.4	-36.9	-18.3	-82.5
Capital expenditures	-0.55	-0.34	-0.44	-0.27	-0.38	-0.27	-0.28	-1.07	-54.4	-12.7
Purchases of investments	-0.12	-4.05	-4.73					0	-165	-120
Cash from investing	1.51	1.86	0.4	-0.29	-0.41	-0.28	-29	24.4	-219	41.2
Stock issued	0	0.48	0.02	0.13	0.53	0	0	0.36	276	0.37
Cash from financing	-0.01	0.52	7.37	0.99	64.7	0.06	0.03	0.79	289	10.3
Net change in cash	-4.21	-3.33	2.73	-2.93	61.4	-7.94	-39.4	-11.8	52.2	-31
Free cash flow	-6.26	-6.05	-5.49	-3.91	-3.22	-7.98	-10.7	-38	-72.7	-95.2
Interest paid	0					0		0.08
Income taxes paid										0.03

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.52 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Return on equity (ROE)	-36.0%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-29.7%	Net income / average total assets.
Return on invested capital (ROIC)	-35.7%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.

Growth

Metric	Value	How it is calculated
Book value growth, 1y	-28.8%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	55.9%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	25.2%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-21.7%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	66.3%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	30.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	14.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	74.5%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	48.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	6.61x	Current assets / current liabilities.
Quick ratio	6.49x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	6.48x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.00x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	0.4%	Total debt / total assets.
Liabilities / assets	17.4%	Total liabilities / total assets.
Net debt	-$235.3M	Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital	$205.0M	Current assets - current liabilities.
Tangible book value	$323.9M	Shareholders' equity - goodwill - intangible assets.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.97	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share	-$1.00	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.77	Cash from operations / diluted weighted shares.
Book value per share	$2.84	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$2.84	Tangible book value / shares outstanding.
Cash per share	$2.08	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$287.7M	Share price x shares outstanding.
Enterprise value	$52.4M	Market cap + total debt - cash - short-term investments.
P/B	0.89x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	0.89x	Market cap / tangible book value, when positive.
FCF yield	-42.1%	Free cash flow / market cap.
Earnings yield	-40.5%	Net income / market cap (the inverse of P/E).

Was Perspective Therapeutics, Inc. profitable in fiscal 2025?

No. It reported a net loss of $103.1M.

How much free cash flow did Perspective Therapeutics, Inc. generate in fiscal 2025?

Cash from operations of $82.5M minus capital expenditures of $12.7M left free cash flow of -$95.2M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Perspective Therapeutics, Inc.